LifePort signs agreement to distribute EpiShuttles in the US and Canada

LifePort is partnering with EpiGuard’s to offer the company’s patient isolation solution to support the fight against Covid-19. The company will design, engineer, manufacture components to adjust the EpiShuttle for a variety of transportation vehicles. Through LifePort, EpiShuttles are currently registered with the FDA and Health Canada.

The EpiShuttle is a single-patient isolation and transport system that provides patient and crew safety while allowing critical care and treatments.

Ellen Catherine Andersen, CEO of EpiGuard, said: “Both crew and aircraft are protected against contamination with the patient placed in an EpiShuttle. At the same time, the patient can receive lifesaving treatment. An ambulance usually requires two to four hours of disinfection between every contagious transport, and with an entire helicopter, it takes almost a day. Because the EpiShuttle is underpressurized and sealed it reduces the need for disinfection, saving valuable time and resources.”

Jason Darley, CEO of LifePort, added: “I am very excited to reach an agreement that leverages the sales, technical and manufacturing capabilities of EpiGuard and LifePort; which will result in increased product availability to the US and Canadian markets.

“I have no doubt that our partnership will increase the safety and functionality of our products in the transport of infected or potentially infected patients.”